EMA Authorised: Verquvo (vericiguat) — Bayer AG

View source ↗

Summary

EMA authorised Verquvo (vericiguat) from Bayer AG for the treatment of heart failure. This marks EU marketing authorisation for the medicine, with the decision …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Verquvo (vericiguat)

Snippet

Status: Authorised. Therapeutic area: Heart Failure. MAH: Bayer AG. Decision date: 26/03/2026